secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001628280-23-015733
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma Q1 net loss $67M; cash $668M; two Phase 1 trials ongoing
---------------------------------------------------------------------------

- GAAP net loss of $67.0M for Q1 2023, compared to $68.1M in Q1 2022; non-GAAP net loss $44.8M vs $50.0M.
- Cash, equivalents and marketable securities of $668.0M as of March 31, 2023; cash runway into 2026.
- Revenue $0.1M, down from $0.6M due to termination of GSK collaboration in December 2022.
- Two Phase 1 trials (LYL797 CAR-T and LYL845 TIL) recruiting at 14 US sites; initial clinical data expected in 2024.
- LYL119 IND submission expected in first half of 2024; abstract at ASGCT May 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828023015733/0001628280-23-015733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828023015733/lyel-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-015733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer